Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Promura GmbH
Deal Size : $2.1 million
Deal Type : Private Placement
Sirona Inks Strategic Investment And JV Deal with Promura GmbH
Details : The proceeds will be used to advance the ongoing research and development of TFC-1067 for the treatment of dyschromia.
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 22, 2025
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Promura GmbH
Deal Size : $2.1 million
Deal Type : Private Placement
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Allergan Aesthetics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Details : Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and...
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 13, 2022
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Allergan Aesthetics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : RODAN & FIELDS LLC
Deal Size : Undisclosed
Deal Type : Termination
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
Details : Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorpo...
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2022
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : RODAN & FIELDS LLC
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study conducted by Dr. Zoe Draelos has been peer reviewed & accepted for publication in the Journal of Cosmetic Dermatology. TFC-1067 demonstrated the ability to lighten dark spots to blend into surrounding skin while preserving overall complexion.
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. TFC-1067 has been clinically proven to selectively lighten dark spots and blend them into surrounding skin tone.
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields
Details : Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067
Details : TFC-1067 demonstrated very good skin compatibility and does not show a sensitizing effect.
Product Name : TFC-1067
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2020
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable